TW200643171A - Porcine circovirus type 2 vaccines - Google Patents

Porcine circovirus type 2 vaccines

Info

Publication number
TW200643171A
TW200643171A TW094118836A TW94118836A TW200643171A TW 200643171 A TW200643171 A TW 200643171A TW 094118836 A TW094118836 A TW 094118836A TW 94118836 A TW94118836 A TW 94118836A TW 200643171 A TW200643171 A TW 200643171A
Authority
TW
Taiwan
Prior art keywords
porcine circovirus
vaccines
circovirus type
pcv2
discovery
Prior art date
Application number
TW094118836A
Other languages
English (en)
Inventor
Gek Joo Chen
Jue Liu
Hui-Kheng Chua
Hwei-Sing Kwang
Original Assignee
Temasek Life Sciences Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Lab Ltd filed Critical Temasek Life Sciences Lab Ltd
Publication of TW200643171A publication Critical patent/TW200643171A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW094118836A 2005-06-07 2005-06-07 Porcine circovirus type 2 vaccines TW200643171A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2005/000182 WO2006132598A1 (en) 2005-06-07 2005-06-07 Porcine circovirus type 2 vaccines

Publications (1)

Publication Number Publication Date
TW200643171A true TW200643171A (en) 2006-12-16

Family

ID=37326423

Family Applications (2)

Application Number Title Priority Date Filing Date
TW094118836A TW200643171A (en) 2005-06-07 2005-06-07 Porcine circovirus type 2 vaccines
TW095120044A TW200716665A (en) 2005-06-07 2006-06-06 Porcine circovirus type 2 vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW095120044A TW200716665A (en) 2005-06-07 2006-06-06 Porcine circovirus type 2 vaccines

Country Status (8)

Country Link
US (1) US9315551B2 (zh)
EP (1) EP1888621A2 (zh)
JP (1) JP2008541780A (zh)
KR (1) KR20080027289A (zh)
CN (1) CN101365713A (zh)
AU (1) AU2006255818B2 (zh)
TW (2) TW200643171A (zh)
WO (2) WO2006132598A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132598A1 (en) 2005-06-07 2006-12-14 Temasek Life Sciences Laboratory Limited Porcine circovirus type 2 vaccines
TWI466682B (zh) * 2006-12-15 2015-01-01 Boehringer Ingelheim Vetmed 以豬第二型環狀病毒（ｐｃｖ２）抗原治療豬
AU2007353480B2 (en) * 2007-05-11 2013-09-19 Temasek Life Sciences Laboratory Limited Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (PCV2) infection
KR20110090711A (ko) * 2010-02-04 2011-08-10 녹십자수의약품(주) 신규한 돼지 써코바이러스 타입 2 및 그의 용도
CN102971425A (zh) 2010-03-16 2013-03-13 弗吉尼亚科技知识产权有限公司 活的减毒嵌合猪圆环病毒疫苗
CN101954074A (zh) * 2010-06-29 2011-01-26 西北农林科技大学 表达pcv-2免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
KR101438542B1 (ko) * 2012-10-16 2014-09-12 고려대학교 산학협력단 돼지 서코바이러스 제2형의 orf3를 이용하는 면역증강제
KR101670469B1 (ko) 2014-10-23 2016-10-28 고려대학교 산학협력단 마이크로ｒｎａ를 유효성분으로 포함하는 돼지 서코바이러스 제2형 감염의 예방 또는 치료용 조성물
CN108431024A (zh) * 2015-10-16 2018-08-21 堪萨斯州立大学研究基金会 猪3型圆环病毒免疫原性组合物以及其制备和使用方法
CN109706127B (zh) * 2019-01-28 2022-08-02 西北农林科技大学 一种猪圆环病毒2型弱毒株PCV2RmA的构建方法
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770380A (en) * 1971-04-19 1973-11-06 Us Army Article and method for multiple immune adherence assay
US4011308A (en) 1974-01-04 1977-03-08 General Electric Company Method for surface immunological detection of biological particles by the use of tagged antibodies
US3876504A (en) * 1974-06-10 1975-04-08 Early Warning Co Procedure for determination of antigens and antibodies and articles for use therewith
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4372745A (en) 1979-12-19 1983-02-08 Electro-Nucleonics, Inc. Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4722890A (en) * 1985-08-27 1988-02-02 The United States Of America As Represented By The Department Of Health And Human Services Quantitative assay for human terminal complement cascade activation
WO1991000047A1 (en) * 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE07008633T1 (de) * 1997-12-11 2008-12-18 Merial Virus des multisystemischen Kümmersyndroms bei Absatzferkeln
US6787142B2 (en) * 2001-04-30 2004-09-07 Government Of Republic Of Singapore Mutant human hepatitis B viral strain and uses thereof
IL140363A0 (en) * 1998-06-19 2002-02-10 Government Of The Republic Of A vaccine-induced hepatitis b viral strain and uses thereof
UA73476C2 (en) * 1998-06-19 2005-08-15 Government Of The Republic Of Singapore Hepatitus b mutant virus strain, nucleic acid isolated molecule, coding mutant main surface antigen of hepatitus b virus strain, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemicalcompound for the treatment of infection of hepatitis virus strain, a composition, a method for screening of liquids of organism for hepatitis b virus, vaccine against hepatitis
WO2000018958A2 (en) * 1998-09-29 2000-04-06 Government Of The Republic Of Singapore An in vitro activity assay for human hepatits b virus (hbv) dna polymerase, the use of such an assay to assay activity of various serum samples and to screen for inhibitors of the hbv dna polymerase and a method of producing hbv dna polymerase
US7037682B2 (en) * 1999-03-13 2006-05-02 Government Of The Republic Of Singapore In vitro activity assay for human hepatitis B virus (HBV) DNA polymerase, and its use for screening for inhibitors of HBV DNA polymerase
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
AU4817299A (en) 1999-06-22 2001-01-09 Institute Of Molecular Agrobiology Detection of salmonella enteritidis
SG83740A1 (en) * 1999-08-10 2001-10-16 Inst Of Molecular Agrobiology An attenuated porcine reproductive and respiratory syndrome virus strain and methods of use
CN1253576C (zh) * 2000-01-19 2006-04-26 分子农业生物学院 Acacia mangium的再生和遗传转化
EP1290016A2 (en) * 2000-06-15 2003-03-12 Purdue Research Foundation Vaccine for congenital tremors in pigs
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
US20040123349A1 (en) * 2002-12-20 2004-06-24 Qi Xie SINAT5, an Arabidopsis thaliana gene promotes ubiquitin related degradation
US7351817B2 (en) * 2003-08-13 2008-04-01 Temasek Life Sciences Laboratory Limited Nucleic acids from rice conferring resistance to bacterial blight disease caused by Xanthomonas spp
US7151206B2 (en) * 2003-11-18 2006-12-19 Temasek Life Sciences Laboratory Arabidopsis argos, a novel gene involved in organ development
WO2006132598A1 (en) 2005-06-07 2006-12-14 Temasek Life Sciences Laboratory Limited Porcine circovirus type 2 vaccines
EP2016614A4 (en) 2006-04-25 2014-04-09 Univ Singapore METHOD OF A ZINC OXIDE FILM GROWN ON THE EPITAXIAL LATERAL AGGREGATE GALLIUM NITRIDE ORIGIN
AU2007353480B2 (en) 2007-05-11 2013-09-19 Temasek Life Sciences Laboratory Limited Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (PCV2) infection

Also Published As

Publication number Publication date
WO2006132605A3 (en) 2007-02-01
US20090221018A1 (en) 2009-09-03
CN101365713A (zh) 2009-02-11
KR20080027289A (ko) 2008-03-26
WO2006132598A1 (en) 2006-12-14
TW200716665A (en) 2007-05-01
US9315551B2 (en) 2016-04-19
AU2006255818B2 (en) 2010-11-25
JP2008541780A (ja) 2008-11-27
WO2006132605A2 (en) 2006-12-14
AU2006255818A1 (en) 2006-12-14
EP1888621A2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
TW200716665A (en) Porcine circovirus type 2 vaccines
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
MY139896A (en) Improved prrs vaccines
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
ZA200801881B (en) Use of surface-active non-enzymatic proteins for washing textiles
EA200701918A1 (ru) Белок липокалин
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
ME01965B (me) Stabilizatori za vakcine osušene zamrzavanjem
WO2011001344A3 (en) Light treatment system
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
IL200253A0 (en) Mite composition
WO2008054481A3 (en) Improved inactivated influenza virus compositions
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
ATE518012T1 (de) Isolate des das reproduktions- und atemwegssyndrom verursachenden schweinevirus und ihre verwendung
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
ZA200705087B (en) Pasteurella multocida vaccine
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
TW200604265A (en) Silicone rubber
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
UA93901C2 (ru) Вакцина против микоплазмы и вируса prrs
CA113787S (en) Lever